Dataset related to the article "Angiogenic and reparative potency of a human cardiac CD90- mesenchymal subpopulation in heart ischemic model"

This record contains raw data related to the article “Angiogenic and reparative potency of a human cardiac CD90- mesenchymal subpopulation in heart ischemic model”. 

Background: Despite recent significant therapeutic progress, cardiovascular diseases (CVD) remain an unmet clinical, economic, and social burden worldwide. Cell-based therapies have been proposed as therapeutic strategies, however, the overall efficacy was modest.

Objective: We aimed to fully characterize a novel subpopulation of CD90- mesenchymal cells derived from human heart tissue (hCmPC90-) and evaluate its ability to induce cardiac tissue repair and functional recovery.

Methods: We performed a comprehensive phenotypic characterization of the hCmPC90- by flow cytometry and RNA sequencing. A direct comparison of hCmPC90- with previously clinically tested bone marrow- and cardiac-derived cell types, has been conducted both in vitro by means of various assays of angiogenic potency, and in vivo, by testing the ability to ameliorate left ventricular function in a mouse model of acute myocardial infarction (AMI).

Results: hCmPC90- showed distinct surface markers and transcriptional phenotype compared with unselected mesenchymal heart cells (hCmPCs) and the positive CD90 counterpart (hCmPC90+). When human hCmPC90-, hCmPC90+, hCmPC, cardiosphere-derived cells (CDCs), and bone marrow-derived CD34+ cells were functionally tested in vitro, hCmPC90- revealed a superior endothelial differentiation ability, higher anti-inflammatory, cardio-protective capacity, and angiocrine activity. Moreover, hCmPC90- showed specific immune-privileged features. When intramyocardially delivered  into infarcted mouse hearts ,  hCmPC90- outperformed three weeks after injection other clinical-grade cell types,  as for left ventricular (LV) function  and adverse LV remodeling recovery, infarct size reduction, and vascular density augmentation. 

Conclusion: hCmPC90- shows a superior biological potency  which deserves clinical exploitation as an advanced therapy medicinal product in the context of refractory ischemic heart disease.

This dataset is not public. It’s available upon reasonable requesto to the corresponding author.